Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 5, 2007, Pages

  Eichenwald, Eric C ^a   Stark, Ann R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; PLACEBO; STEROID;

ARTIFICIAL VENTILATION; BODY GROWTH; BRAIN MALFORMATION; CEREBRAL PALSY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYSTIC PERIVENTRICULAR LEUKOMALACIA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EXTREMELY LOW BIRTH WEIGHT; EXTUBATION; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GROWTH DISORDER; HEAD GROWTH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INFANT MORTALITY; INFECTION; INTELLIGENCE QUOTIENT; LEUKOMALACIA; LONG TERM CARE; LUNG DYSPLASIA; LUNG FUNCTION; MENTAL DEFICIENCY; META ANALYSIS; MOTOR DYSFUNCTION; NERVE CELL DIFFERENTIATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; POSTNATAL CARE; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

ADRENAL CORTEX HORMONES; BRONCHOPULMONARY DYSPLASIA; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, NEWBORN; POSTNATAL CARE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 34548797018     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2006.106583     Document Type: Review

References (31)

1. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk for preterm birth. Cochrane Database Syst Rev 2006;3:CD004454.
2. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU Network: 1997-1197. Pediatrics 2000;106:1070-9.
3. Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institutes of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:e1.
4. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res 2001;50:190-5.
5. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia; a multicenter trial. Pediatrics 2004;114:1649-57.
6. Kothadia JM, O'Shea TM, Roberts D, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999;104:22-7.
7. Stark AR, Waldemar CA, Tyson JE, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. N Engl J Med 2001;344:95-101.
8. Doyle LW, Davis PG, Morley CJ, et al. DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependant infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117:75-83.
9. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001146.
10. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm Infants. Cochrane Database Syst Rev 2003;1:CD001144.
11. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev, 2003;1:CD001145.
12. Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118:e1328-35.
13. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatal 2006;30:227-32.
14. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
15. Romagnoli C, Zecca E, Luciano R, et al. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics 2002;109:85.
16. Romagnoli C, Zecca E, Luciano R, et al. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed 2002;87:55-8.
17. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:177-81.
18. Halliday HL. Early postnatal dexamethasone and cerebral palsy. Pediatrics 2002;109:1168-9.
19. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BCM Pediatrics 2001;1:1.
20. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304-13.
21. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 200;115:655-61.
22. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999;342:1190-6.
23. Flagel SB, Vazquez DM, Watson SJ Jr, et al. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol Regul Integr Comp Physiol 2002;282:R55-63.
24. Baud O, Laudenback V, Edvard P, et al. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001;50:706-11.
25. Karemaker R, Heijnen G, Veen S, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res 2006;60:745-50.
26. Peltomiemi O, Kari A, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr 2005;146:632-7.
27. Halliday H. Guidelines on neonatal steroids. Prenat Neonat Med 2001;6:371-3.
28. American Academy of Pediatrics Committee on Fetus and Newborn. Postnatal steroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:330-8.
29. Shinwell ES, Lerner-Geva L, Lusky A, et al. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007;92:30-3.
30. Walsh MC, Morris BH, Wrage LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatrics 2005;146:798-804.
31. Jobe AH. Postnatal corticosteroids for preterm infants - do what we say, not what we do. N Engl J Med 2004;350:1349-51.